Final data from the GAVRETO ® (pralsetinib) Phase 1/2 ARROW study in RET fusion-positive NSCLC and other solid tumors ...

- Initial data from the ongoing Phase 1b study evaluating R289, a dual IRAK1/4 inhibitor, in LR-MDS- Additional data for REZLIDHIA® (olutasidenib) in patients with mIDH1 AML and MDS Rigel's ...

SOUTH SAN FRANCISCO, June 13, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will present data on fostamatinib disodium hexahydrate (fostamatinib) in two ...

SOUTH SAN FRANCISCO, Calif., June 11, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that data related to TAVALISSE ® (fostamatinib disodium hexahydrate) tablets will ...

SOUTH SAN FRANCISCO, Calif., May 22, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced ...

-- Growing body of data on REZLIDHIA ® (olutasidenib) in mIDH1 relapsed or refractory (R/R) acute myeloid leukemia (AML) patients -- -- New data on olutasidenib in patients with mIDH1 myelodysplastic ...

Title: Efficacy and Safety of Olutasidenib Monotherapy in Primary Refractory AML: A Post Hoc Analysis of a Phase 2 Study Presenter: Antonio Curti, M.D., Ph.D. In the pivotal cohort of R/R AML patients ...

This poster highlights the long-term efficacy and safety of fostamatinib in Japanese patients with primary immune thrombocytopenia (ITP), along with the feasibility of glucocorticoid ...

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the upcoming presentation of four posters highlighting data from their commercial and clinical-stage hematology-oncology portfolio at the ...